At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HEPA Hepion Pharmaceuticals, Inc.
Closed Christmas Day 12-24 13:00:00 EST
0.4999
+0.0000
+0.00%
盘后0.4940
-0.0059-1.18%
13:00 EST
High0.5144
Low0.4610
Vol19.45K
Open0.4990
D1 Closing0.4999
Amplitude10.68%
Mkt Cap3.48M
Tradable Cap3.22M
Total Shares6.96M
T/O9.53K
T/O Rate0.30%
Tradable Shares6.44M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.